Quoin Pharmaceuticals (QNRX) Operating Expenses (2021 - 2026)

Quoin Pharmaceuticals has disclosed Operating Expenses across 6 years of filings, most recently posting $5.5 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 44.3% year-over-year to $5.5 million; the TTM figure through Jun 2026 stood at $19.1 million (up 50.95% YoY), while the FY2025 annual figure was $16.3 million, up 70.97% from the prior year.
• Operating Expenses came in at $5.5 million for Q2 2026 at Quoin Pharmaceuticals, up from $5.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $5.5 million in Q2 2026 to a low of $2.1 million in Q4 2022.
• Average Operating Expenses over 5 years is $3.1 million, with a median of $2.5 million recorded in 2024.
• The largest YoY upside for Operating Expenses was 173.13% in 2022 against a maximum downside of 30.04% in 2022.
• Over 5 years, Operating Expenses stood at $2.1 million in 2022, then grew by 6.32% to $2.2 million in 2023, then climbed by 8.45% to $2.4 million in 2024, then jumped by 87.96% to $4.5 million in 2025, then rose by 21.09% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $5.5 million in Q2 2026, $5.1 million in Q1 2026, and $4.5 million in Q4 2025.